首页> 外文会议>Controlled Release Society Annual Meeting and Exposition >Successful Proof of Concept with ImSus Platform Technology: Preclinical Development of a 1-Month Controlled Release Formulation for a Non-Disclosed Peptide Drug
【24h】

Successful Proof of Concept with ImSus Platform Technology: Preclinical Development of a 1-Month Controlled Release Formulation for a Non-Disclosed Peptide Drug

机译:ImSus平台技术的成功概念验证:未公开多肽药物的1个月控释制剂的临床开发

获取原文

摘要

Microparticle-based controlled release formulations of a non-disclosed peptide drug for subcutaneous application were manufactured by means of Alrise's high-innovative ImSus platform technology. Analytical data and in-vivo release profiles in rats showed excellent results. Both reproducibility and scalability were convincing.
机译:借助Alrise的创新性ImSus平台技术,制造了用于皮下应用的未公开多肽药物的基于微粒的控释制剂。大鼠的分析数据和体内释放曲线显示了极好的结果。可重复性和可扩展性都令人信服。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号